Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates

Cristina Jiménez-Ortigosa; Padmaja Paderu; Mary R. Motyl; David S. Perlin

doi:10.1128/AAC.02145-13

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates

Cristina Jiménez-Ortigosa
, Padmaja Paderu
, Mary R. Motyl
, David S. Perlin

Center for Discovery and Innovation

Public Health Research Institute, New York
Merck

Research output: Contribution to journal › Article › peer-review

118 Scopus citations

Abstract

MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of -(1,3)- glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).

Original language	English
Pages (from-to)	1248-1251
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	58
Issue number	2
DOIs	https://doi.org/10.1128/AAC.02145-13
State	Published - Feb 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.02145-13

Cite this

@article{31acd3120eb24ac39e31cf4c2171f830,

title = "Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates",

abstract = "MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of -(1,3)- glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).",

author = "Cristina Jim{\'e}nez-Ortigosa and Padmaja Paderu and Motyl, \{Mary R.\} and Perlin, \{David S.\}",

year = "2014",

month = feb,

doi = "10.1128/AAC.02145-13",

language = "English",

volume = "58",

pages = "1248--1251",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "2",

}

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates. / Jiménez-Ortigosa, Cristina; Paderu, Padmaja; Motyl, Mary R. et al.
In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 2, 02.2014, p. 1248-1251.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates

AU - Jiménez-Ortigosa, Cristina

AU - Paderu, Padmaja

AU - Motyl, Mary R.

AU - Perlin, David S.

PY - 2014/2

Y1 - 2014/2

N2 - MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of -(1,3)- glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).

AB - MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of -(1,3)- glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC50s).

UR - https://www.scopus.com/pages/publications/84893490335

U2 - 10.1128/AAC.02145-13

DO - 10.1128/AAC.02145-13

M3 - Article

C2 - 24323472

AN - SCOPUS:84893490335

SN - 0066-4804

VL - 58

SP - 1248

EP - 1251

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 2

ER -

Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this